Meeting
2014 Gastrointestinal Cancers Symposium
Effect of dose intensification (DI) of octreotide-LAR (O-LAR) among symptomatic patients with neuroendocrine tumors (NETs).
Authors
Khalid S. Al Efraij
University of British Columbia, Vancouver, BC, Canada
Khalid S. Al Efraij , Mohammed A Aljama , Hagen F. Kennecke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 299)
DOI
10.1200/jco.2014.32.3_suppl.299
Abstract #
299
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy.
First Author: Stijn Hentzen
Poster
2020 Gastrointestinal Cancers Symposium
Exploring telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome (TELEACE): A real-world observational study.
First Author: Michael Morse
Poster
2019 ASCO Annual Meeting
Analysis of patient diaries in the NETTER-1 Study of 177Lu-DOTATATE versus high-dose octreotide in progressive midgut neuroendocrine tumors.
First Author: Jonathan R. Strosberg
Poster
2018 Gastrointestinal Cancers Symposium
The antidiarrheal efficacy of a proprietary amino acid mixture in gastroenteropancreatic neuroendocrine patients.
First Author: Aman Chauhan